[Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review].
作者信息
Tian F Q, Zhang L S, Li J H, Tang M Q, Jiang J, Cheng X H, Zhang X C, Jiang M
机构信息
Department of Hematology, Longgang District People's Hospital of Shenzhen, Shenzhen 518172, China.
Department of Hematology, Lanzhou University Second Hospital, Lanzhou 730030, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2020 Aug 14;41(8):694-696. doi: 10.3760/cma.j.issn.0253-2727.2020.08.016.
Abstract
摘要
相似文献
1
[Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review].维奈托克联合阿扎胞苷治疗老年急性髓系白血病或髓系肉瘤：三例报告及文献综述
Zhonghua Xue Ye Xue Za Zhi. 2020 Aug 14;41(8):694-696. doi: 10.3760/cma.j.issn.0253-2727.2020.08.016.
2
Myeloid sarcoma of the urinary bladder as the presenting feature of secondary acute myeloid leukemia, successfully treated with venetoclax and azacitidine.膀胱髓系肉瘤作为继发性急性髓系白血病的首发表现，经维奈克拉和阿扎胞苷成功治疗。
Ann Hematol. 2024 Feb;103(2):671-672. doi: 10.1007/s00277-023-05529-3. Epub 2023 Nov 9.
3
Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.维奈克拉与阿扎胞苷联合用药是复发/难治性急性髓系白血病患者移植策略的有效过渡方案。
Ann Hematol. 2021 Apr;100(4):1111-1113. doi: 10.1007/s00277-020-04333-7. Epub 2020 Nov 11.
4
[Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].维奈克拉与阿扎胞苷治疗难治性和复发性急性髓系白血病的疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2021 Oct 14;42(10):861-864. doi: 10.3760/cma.j.issn.0253-2727.2021.10.012.
5
Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study.维奈托克联合阿扎胞苷作为晚期急性髓系白血病患者挽救治疗的疗效及预测因素：一项多中心回顾性研究
Leuk Res. 2020 Apr;91:106317. doi: 10.1016/j.leukres.2020.106317. Epub 2020 Feb 14.
6
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。
Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.
7
Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.VIALE-A研究中接受维奈克拉和阿扎胞苷治疗的急性髓系白血病患者缓解后血细胞减少的管理
Am J Hematol. 2022 Nov;97(11):E416-E419. doi: 10.1002/ajh.26692. Epub 2022 Sep 16.
8
Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax.接受阿扎胞苷和维奈克拉治疗的复发/难治性白血病儿科患者的临床反应
Haematologica. 2023 Nov 1;108(11):3142-3147. doi: 10.3324/haematol.2022.282637.
9
Venetoclax plus azacitidine and LDAC induced high response rates in acute myeloid leukaemia in routine clinical practice.在常规临床实践中，维奈克拉联合阿扎胞苷及低剂量阿糖胞苷在急性髓系白血病中诱导出了高缓解率。
Br J Haematol. 2023 Jun;201(5):995-999. doi: 10.1111/bjh.18788. Epub 2023 Mar 31.
10
Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study.VIALE-A研究中CYP3A抑制剂的使用及其对接受维奈克拉联合阿扎胞苷治疗的急性髓系白血病患者结局的影响。
Am J Hematol. 2022 Nov;97(11):E422-E425. doi: 10.1002/ajh.26707. Epub 2022 Sep 16.
引用本文的文献
1
Clinical characteristics, treatment, and prognosis of 118 cases of myeloid sarcoma.118 例髓样肉瘤的临床特征、治疗和预后。
Sci Rep. 2022 Apr 26;12(1):6752. doi: 10.1038/s41598-022-10831-7.
本文引用的文献
1
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.NPM1 突变型 AML 老年患者的预后：现有治疗方法和 Venetoclax 为基础的方案的前景。
Blood Adv. 2020 Apr 14;4(7):1311-1320. doi: 10.1182/bloodadvances.2019001267.
2
Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.维奈克拉联合阿糖胞苷和/或伊达比星治疗复发/难治性儿童急性髓系白血病的 1 期、剂量递增研究。
Lancet Oncol. 2020 Apr;21(4):551-560. doi: 10.1016/S1470-2045(20)30060-7. Epub 2020 Mar 11.
3
Defining Acute Myeloid Leukemia Ontogeny in Older Patients.定义老年患者急性髓系白血病的发生机制。
Clin Lymphoma Myeloma Leuk. 2020 May;20(5):312-315. doi: 10.1016/j.clml.2019.11.007. Epub 2019 Nov 9.
4
How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia.我们如何将维奈托克与低甲基化剂联合用于治疗新诊断的急性髓系白血病患者。
Leukemia. 2019 Dec;33(12):2795-2804. doi: 10.1038/s41375-019-0612-8. Epub 2019 Oct 18.
5
MCL-1 inhibitors - where are we now (2019)?MCL-1 抑制剂——我们现在在哪里（2019 年）？
Expert Opin Ther Pat. 2019 Nov;29(11):909-919. doi: 10.1080/13543776.2019.1672661. Epub 2019 Oct 14.
6
MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2.MicroRNA-497 通过靶向 Bcl-2 抑制多发性骨髓瘤的生长并增加硼替佐米的敏感性。
Int J Mol Med. 2019 Feb;43(2):1058-1066. doi: 10.3892/ijmm.2018.4019. Epub 2018 Dec 7.
7
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.维奈托克联合地西他滨或阿扎胞苷治疗初治老年急性髓系白血病患者。
Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25.
8
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。
Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.
9
Pathways and mechanisms of venetoclax resistance.维奈克拉耐药的途径和机制。
Leuk Lymphoma. 2017 Sep;58(9):1-17. doi: 10.1080/10428194.2017.1283032. Epub 2017 Jan 31.
10
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.阿扎胞苷对比传统治疗方案用于新诊断的原始细胞比例>30%的老年急性髓系白血病患者的国际3期研究。
Blood. 2015 Jul 16;126(3):291-9. doi: 10.1182/blood-2015-01-621664. Epub 2015 May 18.
Zotero 插件